GLPG 3221

Drug Profile

GLPG 3221

Alternative Names: GLPG3221

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer Galapagos NV
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 21 Nov 2017 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Belgium (PO)
  • 20 Jun 2017 Preclinical trials in Cystic fibrosis in Belgium (PO)
  • 20 Jun 2017 Galapagos plans a phase I trial for the triple combination comprising GLPG 3067, GLPG 2222 and GPLG 3221 for Cystic fibrosis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top